International Journal of Health Policy and Management

International Journal of Health Policy and Management

Chinese Physicians’ Preference for Prescribing Brand-Name vs. Generic: A Discrete Choice Experimen

Document Type : Original Article

Authors
Ruilin Wang 1
Zhiyuan Wang 1
Xiaoyu Li 1
Lin Bai 1
Pingan Fan 1
Huangqianyu Li 2
Yuanyuan Tang 3
Xin Li 4
Yangmu Huang 5
Xiaoyan Nie 1, 2
Luwen Shi 1, 2
Jing Chen 1, 2
1 Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China
2 International Research Center for Medicinal Administration, Peking University, Beijing, China
3 Bidding Management Office, Suqian First Hospital, Suqian, China
4 Department of Clinical Pharmacy, School of Pharmacy, Nanjing Medical University, Nanjing, China
5 School of Public Health, Peking University, Beijing, China
10.34172/ijhpm.8392
Abstract
Background 
Promoting the use of generic drugs is a viable strategy to control drug costs. As physicians have a critical role in deciding on what drugs to prescribe and thus whether certified generic drugs were actually used, this study aimed to analyze factors influencing whether physicians were willing to prescribe generic drugs versus brand-name drugs after the implementation of Consistency Evaluation Policy (CEP).
 
Methods 
A discrete choice experiment (DCE) was developed to explore factors influencing physicians’ preferences toward prescribing brand-name drugs versus its certified generic. There were four attributes in the model, namely prices, hospital-level cost control measures, information about clinical safety and efficacy of generic drugs, and reimbursement rate. In total, 1297 physicians from 101 hospitals participated in the study and 1047 questionnaires were retained.
 
Results 
We found that substantial disclosed information about the generic’s clinical safety and efficacy (Sufficient information, odds ratio [OR] = 3.251, 95% CI = 3.098-3.412), lower price of the certified generic (price ratio of generic drugs versus brand-name drugs = 1: 10, OR = 1.130, 95% CI = 1.078-1.185), stringent hospital cost control measures (the brand-name drugs were affected by the national centralized drug procurement (NCDP) policy or a tight cost-control measure, OR = 1.247, 95% CI = 1.190-1.307), and lower reimbursement rates for brand-name drugs (reimbursement rate = 20%, OR = 1.283, 95% CI = 1.224-1.346) all increased physicians’ propensity to prescribe certified generic drugs.
 
Conclusion 
When certified generic drugs were lower priced or disclosed more information about their clinical safety and efficacy or when brand-name drugs were subject to tighter hospital cost control measures, physicians were more inclined to prescribe certified generic drugs. The findings suggest that CEP, together with the NCDP to promote market competition and hospital cost control measures targeting brand-name drugs, promoted the use of generic drugs through influencing physician prescribing behavior. The widely use of generic drugs may further benefit from increased disclosure of the clinical safety and efficacy of generic drugs by their manufacturers. 
Keywords
Prescribing Behavior
Generic Drugs
The Consistency Evaluation Policy
Discrete Choice Model
Influencing Factors
  1. Sacks CA, Van de Wiele VL, Fulchino LA, Patel L, Kesselheim AS, Sarpatwari A. Assessment of variation in state regulation of generic drug and interchangeable biologic substitutions. JAMA Intern Med. 2021;181(1):16-22. doi:1001/jamainternmed.2020.3588
  2. Egilman AC, Wallach JD, Ross JS, Dhruva SS. Medicare spending and potential savings on brand-name drugs with available generic substitutes excluded by 2 large pharmacy benefit managers, 2012 through 2015. JAMA Intern Med. 2018;178(4):567-569. doi:1001/jamainternmed.2017.8016
  3. Kaplan WA, Ritz LS, Vitello M, Wirtz VJ. Policies to promote use of generic medicines in low- and middle-income countries: a review of published literature, 2000-2010. Health Policy. 2012;106(3):211-224. doi:1016/j.healthpol.2012.04.015
  4. Wouters OJ, Kanavos PG, Mc KM. Comparing generic drug markets in Europe and the United States: prices, volumes, and spending. Milbank Q. 2017;95(3):554-601. doi:1111/1468-0009.12279
  5. Gupta R, Shah ND, Ross JS. Generic drugs in the United States: policies to address pricing and competition. Clin Pharmacol Ther. 2019;105(2):329-337. doi:1002/cpt.1314
  6. Patel AN, Kesselheim AS, Rome BN. Frequency of generic drug price spikes and impact on medicaid spending. Health Aff (Millwood). 2021;40(5):779-785. doi:1377/hlthaff.2020.02020
  7. Ding Y. Countermeasure analysis of supply-side structural reform of Chinese pharmaceutical industry. Chin J Pharm. 2019;50(12):1509-1513. doi:16522/j.cnki.cjph.2019.12.020
  8. Howard JN, Harris I, Frank G, Kiptanui Z, Qian J, Hansen R. Influencers of generic drug utilization: a systematic review. Res Social Adm Pharm. 2018;14(7):619-627. doi:1016/j.sapharm.2017.08.001
  9. Leclerc J, Thibault M, Midiani Gonella J, Beaudoin C, Sampalis J. Are generic drugs used in cardiology as effective and safe as their brand-name counterparts? A systematic review and meta-analysis. Drugs. 2020;80(7):697-710. doi:1007/s40265-020-01296-x
  10. Cook JW, McGrath MK, Dixon MD, Switchenko JM, Harvey RD, Pentz RD. Academic oncology clinicians' understanding of biosimilars and information needed before prescribing. Ther Adv Med Oncol. 2019;11:1758835918818335. doi:1177/1758835918818335
  11. Bohn J, Kortepeter C, Muñoz M, Simms K, Montenegro S, Dal Pan G. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs. Clin Pharmacol Ther. 2015;97(5):508-517. doi:1002/cpt.81
  12. Serebruany VL, Hall TS, Atar D, et al. Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System. Eur Heart J Cardiovasc Pharmacother. 2019;5(4):210-215. doi:1093/ehjcvp/pvy035
  13. Benvenga S, Carlé A. Levothyroxine formulations: pharmacological and clinical implications of generic substitution. Adv Ther. 2019;36(Suppl 2):59-71. doi:1007/s12325-019-01079-1
  14. Medeiros M, Lumini J, Stern N, Castañeda-Hernández G, Filler G. Generic immunosuppressants. Pediatr Nephrol. 2018;33(7):1123-1131. doi:1007/s00467-017-3735-z
  15. Dunne SS. What do users of generic medicines think of them? A systematic review of consumers' and patients' perceptions of, and experiences with, generic medicines. Patient. 2016;9(6):499-510. doi:1007/s40271-016-0176-x
  16. Du Z, Jiang Y, Shen Y, et al. Reevaluation of adverse drug reactions of psychiatric drugs under the Chinese drug volume-based procurement policy. BMC Health Serv Res. 2022;22(1):424. doi:1186/s12913-022-07851-4
  17. Long H, Yang Y, Geng X, Mao Z, Mao Z. Changing characteristics of pharmaceutical prices in China under centralized procurement policy: a multi-intervention interrupted time series. Front Pharmacol. 2022;13:944540. doi:3389/fphar.2022.944540
  18. Yang P, Fujimura S, Du Y, et al. Comparison of pharmaceutical characteristics between brand-name meropenem and its generics. Antibiotics (Basel). 2021;10(9):1096. doi:3390/antibiotics10091096
  19. Wei Y, Zhu J, Qiao J, Zhang D, Chen Y. The impact of the consistency evaluation policy of generic drugs on R&D investment intensity of pharmaceutical companies-an empirical study based on the difference-in-differences model. Front Public Health. 2022;10:902025. doi:3389/fpubh.2022.902025
  20. Lin SY, Baumann K, Zhou C, Zhou W, Cuellar AE, Xue H. Trends in use and expenditures for brand-name statins after introduction of generic statins in the US, 2002-2018. JAMA Netw Open. 2021;4(11):e2135371. doi:1001/jamanetworkopen.2021.35371
  21. Dickson SR, Kent T. Association of generic competition with price decreases in physician-administered drugs and estimated price decreases for biosimilar competition. JAMA Netw Open. 2021;4(11):e2133451. doi:1001/jamanetworkopen.2021.33451
  22. Newman-Casey PA, Woodward MA, Niziol LM, Lee PP, De Lott LB. Brand medications and Medicare Part D: how eye care providers' prescribing patterns influence costs. Ophthalmology. 2018;125(3):332-339. doi:1016/j.ophtha.2017.05.024
  23. Olsson P, Freij J, Compagno Strandberg M, et al. Physicians' attitudes toward generic substitutions of antiseizure drugs in epilepsy. Acta Neurol Scand. 2021;144(5):600-607. doi:1111/ane.13504
  24. Dunne SS, Dunne CP. What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs. BMC Med. 2015;13:173. doi:1186/s12916-015-0415-3
  25. Domeyer PJ, Katsari V, Sarafis P, Aletras V, Niakas D. Greek students' attitudes, perception and knowledge regarding generic medicines in times of economic crisis: a cross-sectional study. BMC Med Educ. 2018;18(1):262. doi:1186/s12909-018-1379-8
  26. Dunne S, Shannon B, Hannigan A, Dunne C, Cullen W. Physician and pharmacist perceptions of generic medicines: what they think and how they differ. Health Policy. 2014;116(2-3):214-223. doi:1016/j.healthpol.2014.03.007
  27. Kalkan A, Roback K, Hallert E, Carlsson P. Factors influencing rheumatologists' prescription of biological treatment in rheumatoid arthritis: an interview study. Implement Sci. 2014;9:153. doi:1186/s13012-014-0153-5
  28. Chen X, Zhang T, Wang H, et al. Factors influencing the prescription pattern of essential medicines from the perspectives of general practitioners and patients: a qualitative study in China. BMJ Open. 2022;12(5):e055091. doi:1136/bmjopen-2021-055091
  29. Johnson CF, Williams B, MacGillivray SA, Dougall NJ, Maxwell M. 'Doing the right thing': factors influencing GP prescribing of antidepressants and prescribed doses. BMC Fam Pract. 2017;18(1):72. doi:1186/s12875-017-0643-z
  30. Xue Q, Xiong X, Feng Y, Yao L, Chen S, Xiang L. Socioeconomic factors influencing antipsychotic prescription for schizophrenia inpatients in China: a cross-sectional study. Int Clin Psychopharmacol. 2014;29(5):288-295. doi:1097/yic.0000000000000024
  31. Buusman A, Andersen M, Merrild C, Elverdam B. Factors influencing GPs' choice between drugs in a therapeutic drug group. A qualitative study. Scand J Prim Health Care. 2007;25(4):208-213. doi:1080/02813430701652036
  32. Irawati S, Prayudeni S, Rachmawati R, et al. Key factors influencing the prescribing of statins: a qualitative study among physicians working in primary healthcare facilities in Indonesia. BMJ Open. 2020;10(6):e035098. doi:1136/bmjopen-2019-035098
  33. Yip W, Fu H, Chen AT, et al. 10 years of health-care reform in China: progress and gaps in universal health coverage. Lancet. 2019;394(10204):1192-1204. doi:1016/s0140-6736(19)32136-1
  34. Zhu Z, Wang Q, Sun Q, Lexchin J, Yang L. Improving access to medicines and beyond: the national volume-based procurement policy in China. BMJ Glob Health. 2023;8(7):e011535. doi:1136/bmjgh-2022-011535
  35. Ng NM, Ng YS, Chu TK, Lau P. Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study. BMC Prim Care. 2022;23(1):317. doi:1186/s12875-022-01928-z
  36. Teixeira Rodrigues A, Roque F, Falcão A, Figueiras A, Herdeiro MT. Understanding physician antibiotic prescribing behaviour: a systematic review of qualitative studies. Int J Antimicrob Agents. 2013;41(3):203-212. doi:1016/j.ijantimicag.2012.09.003
  37. Zhou X, Zhang X, Yang L, et al. Influencing factors of physicians' prescription behavior in selecting essential medicines: a cross-sectional survey in Chinese county hospitals. BMC Health Serv Res. 2019;19(1):980. doi:1186/s12913-019-4831-5
  38. Bolmsjö BB, Palagyi A, Keay L, Potter J, Lindley RI. Factors influencing deprescribing for residents in advanced care facilities: insights from general practitioners in Australia and Sweden. BMC Fam Pract. 2016;17(1):152. doi:1186/s12875-016-0551-7
  39. Wang Z, Wang R, Li X, et al. Influencing factors of generic prescribing behavior of physicians: a structural equation model based on the theory of planned behavior. Risk Manag Healthc Policy. 2024;17:1375-1385. doi:2147/rmhp.S446743
  40. Xu Liping LY, Shi Luwen. Empirical study on prices of generics and their originators in China. 2009 Annual Meeting of the Pharmaceutical Affairs Management Committee of the Chinese Pharmaceutical Association and Forum on "Research on the Revision of the National Drug Policy and Drug Administration Law".
  41. Zhang Chi H, Shi Luwen, et al. Empirical research of price difference and market share between brand-name drugs and generics in one province in China. Proceedings of the 2018 Annual Meeting and Academic Symposium of the Pharmaceutical Affairs Management Committee of the Chinese Pharmaceutical Association; 2018.
  42. Xu Liping LY, Shi Luwen. Price Comparison between Brand Name Drugs and Generics in China. 2009 Annual Meeting of the Pharmaceutical Affairs Management Committee of the Chinese Pharmaceutical Association and Forum on "Research on the Revision of the National Drug Policy and Drug Administration Law.
  43. Zhang Chi H, Shi Luwen, et al. Empirical research of price difference and market share between brand-name drugs and generics in one province in China. Proceedings of the 2018 Annual Meeting and Academic Symposium of the Pharmaceutical Affairs Management Committee of the Chinese Pharmaceutical Association; 2018.
  44. Wang N, Yang Y, Xu L, Mao Z, Cui D. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis. BMC Public Health. 2021;21(1):1883. doi:1186/s12889-021-11882-7
  45. Brennan TA, Lee TH. Allergic to generics. Ann Intern Med. 2004;141(2):126-130. doi:7326/0003-4819-141-2-200407200-00011
  46. Crea G, Galizzi MM, Linnosmaa I, Miraldo M. Physician altruism and moral hazard: (no) evidence from Finnish national prescriptions data. J Health Econ. 2019;65:153-169. doi:1016/j.jhealeco.2019.03.006
  47. Acuña AJ, Mengers SR, Raji Y, et al. Opioid-prescribing patterns among shoulder and elbow surgeons: considerations for future prescription guidelines. J Shoulder Elbow Surg. 2021;30(8):e531-e538. doi:1016/j.jse.2020.12.001
  48. Liu C, Liu C, Wang D, Zhang X. Intrinsic and external determinants of antibiotic prescribing: a multi-level path analysis of primary care prescriptions in Hubei, China. Antimicrob Resist Infect Control. 2019;8:132. doi:1186/s13756-019-0592-5
  49. Vandergrift JL, Weng W, Gray BM. The association between physician knowledge and inappropriate medications for older populations. J Am Geriatr Soc. 2021;69(12):3584-3594. doi:1111/jgs.17413
  50. Fernandez-Lazaro CI, Brown KA, Langford BJ, Daneman N, Garber G, Schwartz KL. Late-career physicians prescribe longer courses of antibiotics. Clin Infect Dis. 2019;69(9):1467-1475. doi:1093/cid/ciy1130
  51. De Bruyne F, Ponçon A, Giai J, et al. INN or brand name drug prescriptions: a multilevel, cross-sectional study in general practice. Eur J Clin Pharmacol. 2019;75(2):275-283. doi:1007/s00228-018-2580-8
  52. Mishra A, Read SH, Rochon PA. Influence of physician sex and gender on prescribing practices among older adults. J Am Geriatr Soc. 2020;68(12):2764-2767. doi:1111/jgs.16851
  53. Maust DT, Lin LA, Blow FC, Marcus SC. County and physician variation in benzodiazepine prescribing to Medicare beneficiaries by primary care physicians in the USA. J Gen Intern Med. 2018;33(12):2180-2188. doi:1007/s11606-018-4670-9
  54. Rome BN, Sarpatwari A, Kesselheim AS. State laws and generic substitution in the year after new generic competition. Value Health. 2022;25(10):1736-1742. doi:1016/j.jval.2022.03.012
  55. Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Med. 2007;4(9):e283. doi:1371/journal.pmed.0040283
  56. Schutte T, Tichelaar J, Nanayakkara P, Richir M, van Agtmael M. Students and doctors are unaware of the cost of drugs they frequently prescribe. Basic Clin Pharmacol Toxicol. 2017;120(3):278-283. doi:1111/bcpt.12678
  57. Yip W, Hsiao W. Harnessing the privatisation of China's fragmented health-care delivery. Lancet. 2014;384(9945):805-818. doi:1016/s0140-6736(14)61120-x
  58. Zhang A, Nikoloski Z, Albala SA, Yip W, Xu J, Mossialos E. Patient choice of health care providers in China: primary care facilities versus hospitals. Health Syst Reform. 2020;6(1):e1846844. doi:1080/23288604.2020.1846844
  59. Kesselheim AS, Gagne JJ, Franklin JM, et al. Variations in patients' perceptions and use of generic drugs: results of a national survey. J Gen Intern Med. 2016;31(6):609-614. doi:1007/s11606-016-3612-7
  60. Flood D, Mathieu I, Chary A, García P, Rohloff P. Perceptions and utilization of generic medicines in Guatemala: a mixed-methods study with physicians and pharmacy staff. BMC Health Serv Res. 2017;17(1):27. doi:1186/s12913-017-1991-z
  61. Ryu M, Kim J. Perception and attitude of Korean physicians towards generic drugs. BMC Health Serv Res. 2017;17(1):610. doi:1186/s12913-017-2555-y
  62. El-Jardali F, Fadlallah R, Morsi RZ, et al. Pharmacists' views and reported practices in relation to a new generic drug substitution policy in Lebanon: a mixed methods study. Implement Sci. 2017;12(1):23. doi:1186/s13012-017-0556-1
  63. Arroyo R, Sempere AP, Ruiz-Beato E, et al. Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study. BMJ Open. 2017;7(3):e014433. doi:1136/bmjopen-2016-014433
  64. de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015;8(5):373-384. doi:1007/s40271-015-0118-z
  65. Ozechowski TJ, Turner CW, Hops H. Mixed-effects logistic regression for estimating transitional probabilities in sequentially coded observational data. Psychol Methods. 2007;12(3):317-335. doi:1037/1082-989x.12.3.317
  66. Fenwick EK, Ozdemir S, Man REK, et al. Development and validation of a preference-based glaucoma utility instrument using discrete choice experiment. JAMA Ophthalmol. 2021;139(8):866-874. doi:1001/jamaophthalmol.2021.1874
  67. Vrieze SI. Model selection and psychological theory: a discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC). Psychol Methods. 2012;17(2):228-243. doi:1037/a0027127
  68. Steinman MA, Landefeld CS. Overcoming inertia to improve medication use and deprescribing. JAMA. 2018;320(18):1867-1869. doi:1001/jama.2018.16473
  69. Costa-Font J, Rudisill C, Tan S. Brand loyalty, patients and limited generic medicines uptake. Health Policy. 2014;116(2-3):224-233. doi:1016/j.healthpol.2014.01.015
  70. Perucca E. The safety of generic substitution in epilepsy. Lancet Neurol. 2016;15(4):344-345. doi:1016/s1474-4422(16)00042-9
  71. Ross JS. Therapeutic substitution-should it be systematic or automatic? JAMA Intern Med. 2016;176(6):776. doi:1001/jamainternmed.2016.2271
  72. Singh S. The safety of generic prescription drugs in the United States. Drug Saf. 2018;41(4):325-328. doi:1007/s40264-017-0632-0
  73. Perazzo H, Castro R, Luz PM, et al. Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis. Bull World Health Organ. 2020;98(3):188-197k. doi:2471/blt.19.231522
  74. Tamargo J, Rosano G. Low quality of some generic cardiovascular medicinal products represents a matter for growing concern. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):176-187. doi:1093/ehjcvp/pvz037
  75. Abozeid M, Alsebaey A, Abdelsameea E, et al. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C. Int J Infect Dis. 2018;75:109-114. doi:1016/j.ijid.2018.07.025
  76. Ren XY ea. Experience and implications of generic drug substitution promotion policies in typical countries outside the region. China Health Policy Research. 2023;16(12):49-55.
  77. Qu J, Zuo W, Took RL, et al. A nationwide survey exploring physicians' and pharmacists' knowledge, awareness and perceptions regarding generic medicines in China. BMC Health Serv Res. 2022;22(1):1069. doi:1186/s12913-022-08438-9
  78. Yan W, Zhou YY, Liu YT, et al. Investigation and analysis of Chinese residents' cognition of generic drugs and related factors. Chinese Journal of Hospital Pharmacy. 2022;42(18):1943-1947. doi:13286/ J.1001-5213.2022.18.17
  79. Yasaitis L, Gupta A, Newcomb C, Kim E, Newcomer L, Bekelman J. An insurer's program to incentivize generic oncology drugs did not alter treatment patterns or spending on care. Health Aff (Millwood). 2019;38(5):812-819. doi:1377/hlthaff.2018.05083
  80. Dave CV, Kesselheim AS, Fox ER, Qiu P, Hartzema A. High generic drug prices and market competition: a retrospective cohort study. Ann Intern Med. 2017;167(3):145-151. doi:7326/m16-1432
  81. Seidman G, Atun R. Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries. BMJ Glob Health. 2017;2(2):e000243. doi:1136/bmjgh-2016-000243
  82. Chen Y, Ji X, Xiao H, et al. Impact of the pilot volume-based drug purchasing policy in China: interrupted time-series analysis with controls. Front Pharmacol. 2021;12:804237. doi:3389/fphar.2021.804237
  83. Yuan J, Lu ZK, Xiong X, Jiang B. Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China. BMJ Glob Health. 2021;6(9):e005519. doi:1136/bmjgh-2021-005519
  84. Chen L, Yang Y, Luo M, Hu B, Yin S, Mao Z. The impacts of national centralized drug procurement policy on drug utilization and drug expenditures: the case of Shenzhen, China. Int J Environ Res Public Health. 2020;17(24):9415. doi:3390/ijerph17249415
  85. Newcomer LN. Changing physician incentives for cancer care to reward better patient outcomes instead of use of more costly drugs. Health Aff (Millwood). 2012;31(4):780-785. doi:1377/hlthaff.2012.0002
  86. Zhao C, Wang C, Shen C, Wang Q. Diagnosis-related group (DRG)-based case-mix funding system, a promising alternative for fee for service payment in China. Biosci Trends. 2018;12(2):109-115. doi:5582/bst.2017.01289
  87. Wu Q, Zhao Z, Xie X. Establishment and application of the performance appraisal system for hierarchical diagnosis and treatment in China: a case study in Fujian province. Front Public Health. 2023;11:1008863. doi:3389/fpubh.2023.1008863
  88. Fischer KE, Koch T, Kostev K, Stargardt T. The impact of physician-level drug budgets on prescribing behavior. Eur J Health Econ. 2018;19(2):213-222. doi:1007/s10198-017-0875-9
  89. Zhao M, Zhang L, Feng Z, Fang Y. Physicians' knowledge, attitude and practice of generic substitution in China: a cross-sectional online survey. Int J Environ Res Public Health. 2021;18(15):7749. doi:3390/ijerph18157749
  90. Colgan SL, Faasse K, Pereira JA, Grey A, Petrie KJ. Changing perceptions and efficacy of generic medicines: an intervention study. Health Psychol. 2016;35(11):1246-1253. doi:1037/hea0000402
  91. Qu J, Zuo W, Wang S, et al. Knowledge, perceptions and practices of pharmacists regarding generic substitution in China: a cross-sectional study. BMJ Open. 2021;11(10):e051277. doi:1136/bmjopen-2021-051277
International Journal of Health Policy and Management
Volume 13, Issue 1
2024
Pages 1-9

XML
PDF 719.87 K
Supplementary File
(IJHPM does not take responsibility for any information provided in the supplementary files.)
Wang-Supple-File-1-IJHPM.pdf
Sample Size DCE.R
Wang-Supple-File-3-IJHPM.pdf

  • Received Date 07 February 2024
  • Revised Date 11 November 2024
  • Accepted Date 11 December 2024
  • First Published Date 11 December 2024
  • Published Date 01 December 2024